Abstract:Introduction: The 2013 AHA/ACC Guideline recommended limiting saturated fatty acids (SFA) and substituting SFA with monounsaturated fatty acids (MUFA) or polyunsaturated fatty acids (PUFA) in diet. Dietary intake data derived from self-reports is prone to measurement error and studies have been criticized for this reason. An objective alternative approach to examining the role of different dietary fatty acids on coronary heart disease (CHD) risk is to measure plasma phospholipid fatty acid (PL-FA) profiles, which reflect both dietary intake and endogenous metabolism, hence are proximal to the pathophysiologic processes of CHD. Our aim was to evaluate the role of plasma PL-FA profiles on CHD risk both directly and by estimating the theoretical effects of plasma “substitution” of various fatty acids for each other on CHD risk, and evaluate the consistence with the AHA/ACC Guideline. Hypothesis: Plasma SFA is associated with increased CHD risk, and “substituting” plasma SFA with MUFA, PUFA n-6 or n-3 is associated with lower CHD risk. Methods: We performed a nested case-control study with 2428 postmenopausal women in Women’s Health Initiative Observational Study (1214 CHD cases-controls pairs matched for baseline age, enrollment date, ethnicity and hysterectomy). Plasma PL-FA profiles were measured using gas chromatography methodology and expressed as molar percentage (mol%). Multivariate conditional logistic regression was used to calculate ORs for CHD risk associated with 1 mol% PL-FA increase, and “substitutions” of various fatty acids for each other, adjusting for matching factors, physical activity, body mass index (BMI), smoking, family history of diabetes, anticoagulant medication, hormone therapy, hypertension, diabetes mellitus, dyslipidemia and alternative healthy eating index. In addition, we tested the interactions of BMI and hormone therapy with PL-FAs. Results: In multivariate conditional logistic regression analysis, plasma PL SFA was associated with increased CHD risk (OR=1.16, 95% CI 1.09 to 1.24) and PUFA n-3 was associated with decreased CHD risk (OR=0.92, 95% CI 0.86 to 0.97). No significant associations were observed for MUFA, PUFA n-6 and trans -fatty acids. “Substituting” 1 mol% SFA with an equivalent proportion of MUFA, PUFA n-6, or n-3 were associated with lower CHD risk (OR=0.81, 95% CI 0.74 to 0.88; OR=0.77, 95% CI 0.70 to 0.84;and OR=0.85, 95%CI 0.80 to 0.92, respectively). “Substituting” PUFA n-6 with n-3 was associated with lower CHD risk (OR=0.92, 95% CI 0.86 to 0.98) while no significant effect was found for “substituting” PUFA n-6 with MUFA. No significant interactions were obtained of BMI and hormone therapy with PL-FAs. Conclusion: This plasma PL-FA “substitution” analysis is consistent with the AHA/ACC Guideline and suggests that “substituting” PL SFA with MUFA, PUFA n-6 or n-3, and “substituting” PUFA n-6 with n-3 is associated with lower CHD risk.

Abstract MP38: Plasma Lipophilic Index and Risk of Coronary Heart Disease in Postmenopausal Women

Higher Lipophilic Index Indicates Higher Risk of Coronary Heart Disease in Postmenopausal Women

Plasma Phospholipid Fatty Acids and Coronary Heart Disease Risk: A Matched Case-Control Study Within the Women's Health Initiative Observational Study.

Abstract MP39: Plasma Phospholipid Fatty Acid and Coronary Heart Disease Risk

Evaluation of lipoprotein-associated Phospholipase A2 in Healthy Chinese Han Adult Serum

Biomarker of Long-Chain n-3 Fatty Acid Intake and Breast Cancer: Accumulative Evidence from an Updated Meta-Analysis of Epidemiological Studies.

Relationship Between the N-3 Index, Serum Metabolites and Breast Cancer Risk.

Low Docosahexaenoic Acid Content in Plasma Phospholipids is Associated with Increased Non-alcoholic Fatty Liver Disease in China

Circulating Fatty Acids, Genetic Risk, and Incident Coronary Artery Disease: A Prospective, Longitudinal Cohort Study.

A Significant Inverse Relationship Between Concentrations of Plasma Homocysteine and Phospholipid Docosahexaenoic Acid in Healthy Male Subjects.

Abstract MP40: Postprandial Lipemia and the Risk of Coronary Heart Disease and Stroke. The Atherosclerosis Risk in Communities (ARIC) Study

Atherogenic index of plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women

Lipoprotein subclasses and endogenous sex hormones in women at midlife

Abstract MP62: Fatty Acid Biomarkers of 15:0, 17:0 and Trans 16:1n-7 and Incident Coronary Heart Disease and Stroke: A Pooling Project of 15 Prospective Cohorts in the Fatty Acids and Outcomes Research Consortium

Metabolomics Biomarkers for Fatty Acid Intake and Biomarker-Calibrated Fatty Acid Associations with Chronic Disease Risk in Postmenopausal Women

P2248Impact of Lipoprotein (a) Levels on the Presence and Severity of Coronary Artery Disease in Female Patients: a Large Cross-Sectional Chinese Cohort Study

Plasma phospholipid very-long-chain SFAs in midlife and 20-year cognitive change in the Atherosclerosis Risk in Communities (ARIC): a cohort study

Low-density lipoprotein subclasses over the menopausal transition and risk of coronary calcification and carotid atherosclerosis: the SWAN Heart and HDL ancillary studies

Metabolomics-Based Biomarker for Dietary Fat and Associations with Chronic Disease Risk in Postmenopausal Women1

Changes in Plasma Phospholipid Fatty Acid Profiles over 13 Years and Correlates of Change: European Prospective Investigation into Cancer and Nutrition-Norfolk Study.

Blood Levels of Omega-6 Polyunsaturated Fatty Acids and Coronary Heart Disease: an Updated Meta-Analysis of Epidemiological Studies